Extensive Stage Small Cell Lung Cancer Market Size is predicted exhibit a 7.4% CAGR during the forecast period for 2023-2031.
Small cell lung cancer (SCLC ) is a kind of cancer that affects lung tissue. SCLC has two stages limited and extensive stage. Extensive stage small cell lung cancer (SCLC) proliferates throughout one lung, both lungs or other body parts, making it difficult to treat. There is no complete cure treatment available for extensive-stage SCLC. However, chemotherapy, radiation therapy, and other treatments can be used to maintain the quality of patients' life, improve symptoms, and prolong life.
Recent advanced studies in the molecular biology of SCLC may open up opportunities for molecularly informed therapeutic strategies for patients with SCLC, which could significantly improve the outcome of this disease.
Significant competitors in the global market for extensive-stage small-cell lung cancer are always looking for cooperation opportunities to improve their market positions and increase their market penetration. The information is published after thorough research, analysis of market trends, significant events, fresh initiatives, and technological advancements and innovations. The report examines various market participants in the industry. The major corporations are employing multiple methods, including alliances, mergers, acquisitions, and others, which are further anticipated to accelerate market expansion and increase their market presence and share.
The increasing prevalence of extensive stage small cell lung cancer is expected to expand the demand for the market during the forecast period. For instance, according to the American Cancer Society (ACS), Lung cancer (both small cell and non-small cell) is the second most expected cancer in the United States. In 2023, there will be 238,340 new cases of lung cancer and around 127,070 deaths from lung cancer.
Introducing checkpoint inhibitors in the extensive stage of small cell lung cancer therapies can improve the safety and effectiveness of the treatment, which will help maximize the therapeutic potential of cancer treatments. Hence, the introduction of checkpoint inhibitors is anticipated to accelerate the market growth opportunities in the upcoming future.
The side effects associated with chemotherapies and limitations related to cancer therapies & drugs are expected to impede the market expansion during the forecast period. In addition, the high cost of medicines and treatments is also going to hinder market expansion.
The global Extensive Stage Small Cell Lung Cancer Market is segregated based on product and region. Based on product, the market segmentation is divided into commercial and clinical. The clinical segment is anticipated to dominate the market soon. According to the WHO, cancer cases will rise to 29.4 million by 2040, which is expected to boost the need for advanced cancer treatments, thereby surging the market demand over the projected period.
North America region is anticipated to lead the global extensive-stage small cell lung cancer market over the forecast period. The growth is attributed to the presence of developed healthcare infrastructure and permitted reimbursement policies for medical treatments. Furthermore, the rising prevalence of extensive-stage small lung cancer is estimated to drive the North American market during the projected period.
The Asia-Pacific region is anticipated to hold the maximum share of the market in the near future. The high prevalence of cancers and unmet medical needs will likely drive new growth opportunities for market players in this region. In addition, R&D efforts for manufacturing effective therapies and rising government initiatives in developing to improve public awareness regarding cancer diseases are expected to propel further the extensive stage small cell lung cancer market.
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 7.4 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product and Region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Jazz Pharmaceuticals Plc, G1 Therapeutics Inc., Lee's Pharmaceutical Limited, Shanghai Henlius Biotech, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beigene Ltd. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Extensive Stage Small Cell Lung Cancer Market Snapshot
Chapter 4. Global Extensive Stage Small Cell Lung Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2022 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following by Products:
5.2.1. Zepzelca (Lurbinectedine)
5.2.2. Cosela (Trilaciclib)
5.2.3. Tecentriq (Atezolizumab)
5.2.4. Imfinzi (Durvalumab)
5.2.5. Other Pipeline Products
5.2.5.1. HLX10 (Serplulimab/Hansizhuang)
5.2.5.2. Socazolimab (ZKAB001)
5.2.5.3. SHR-1316 (Adebrelimab)
5.2.5.4. Tislelizumab
Chapter 6. Extensive Stage Small Cell Lung Cancer Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) estimates and forecasts by Products, 2023-2031
6.1.2. North America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
6.2. Europe
6.2.1. Europe Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, 2023-2031
6.2.2. Europe Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.3. Asia Pacific
6.3.1. Asia Pacific Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, 2023-2031
6.3.2. Asia Pacific Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.4. Latin America
6.4.1. Latin America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, (US$ Million) 2023-2031
6.4.2. Latin America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, (US$ Million) 2023-2031
6.5.2. Middle East & Africa Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. F. Hoffmann-La Roche Ltd
7.2.2. AstraZeneca PLC
7.2.3. Jazz Pharmaceuticals Plc
7.2.4. G1 Therapeutics Inc.
7.2.5. Shanghai Henlius Biotech, Inc.
7.2.6. Lee's Pharmaceutical Limited
7.2.7. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
7.2.8. Beigene Ltd.
7.2.9. Other Prominent Players
Global Extensive Stage Small Cell Lung Cancer Market, By Products
Global Extensive Stage Small Cell Lung Cancer Market, By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
